APRE Aprea Therapeutics, Inc. Stock Quote

APRE [NASD]

Index	-	P/E	-	EPS (ttm)	-1.65	Insider Own	4.90%	Shs Outstand	21.90M	Perf Week	-5.94%
Market Cap	19.18M	Forward P/E	-	EPS next Y	-1.37	Insider Trans	4.51%	Shs Float	17.43M	Perf Month	-4.06%
Income	-35.40M	PEG	-	EPS next Q	-0.40	Inst Own	20.70%	Short Float	6.72%	Perf Quarter	-55.05%
Sales	-	P/S	-	EPS this Y	31.10%	Inst Trans	-19.11%	Short Ratio	3.07	Perf Half Y	-73.51%
Book/sh	1.99	P/B	0.40	EPS next Y	11.20%	ROA	-58.70%	Target Price	2.00	Perf Year	-83.78%
Cash/sh	1.96	P/C	0.40	EPS next 5Y	-	ROE	-68.20%	52W Range	0.62 - 5.89	Perf YTD	-72.59%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-86.64%	Beta	-
Dividend %	-	Quick Ratio	7.40	Sales past 5Y	-	Gross Margin	-	52W Low	26.89%	ATR	0.09
Employees	16	Current Ratio	7.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.26	Volatility	10.01% 10.54%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	20.60%	Profit Margin	-	Rel Volume	0.41	Prev Close	0.81
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	381.24K	Price	0.79
Recom	3.00	SMA20	-4.23%	SMA50	-24.26%	SMA200	-71.19%	Volume	157,011	Change	-2.88%

Dec-28-20

Downgrade

Robert W. Baird

Outperform → Neutral

Dec-16-20

Initiated

Berenberg

Buy

$37

Sep-29-20

Resumed

JP Morgan

Neutral

$25

Jun-22-20

Initiated

H.C. Wainwright

Neutral

$30

Apr-21-20

Initiated

Robert W. Baird

Outperform

$45

Oct-28-19

Initiated

RBC Capital Mkts

Outperform

$33

Oct-28-19

Initiated

Morgan Stanley

Equal-Weight

$23

Oct-28-19

Initiated

JP Morgan

Neutral

$23

May-19-22 06:30AM	The Petri Dish: Taiho acquires Cullinan cancer subsidiary in $405M deal American City Business Journals
May-16-22 09:21AM	Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results GlobeNewswire -19.09%
Mar-15-22 04:15PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations GlobeNewswire +5.45%
Mar-02-22 04:41AM	Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Jan-14-22 10:00AM	Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks
Jan-06-22 08:00AM	Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 GlobeNewswire
Dec-14-21 08:00AM	Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting GlobeNewswire -10.05%
Dec-13-21 08:00AM	Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting GlobeNewswire -10.85%
Dec-10-21 10:30AM	Aprea (APRE) Reports FDA Removal of Clinical Hold on Study Zacks
Dec-09-21 12:30PM	FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies Benzinga
08:00AM	Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies GlobeNewswire
Nov-08-21 04:15PM	Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations GlobeNewswire
Nov-04-21 04:15PM	Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting GlobeNewswire
Sep-21-21 08:39AM	Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO Benzinga
07:01AM	18 Stocks Moving in Tuesday's Pre-Market Session Benzinga
Sep-20-21 04:15PM	Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021 GlobeNewswire
08:42AM	Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock? Zacks
Sep-14-21 08:00AM	Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021 GlobeNewswire
Sep-03-21 07:21AM	Are Institutions Heavily Invested In Aprea Therapeutics, Inc.'s (NASDAQ:APRE) Shares? Simply Wall St.
Aug-12-21 04:15PM	Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations GlobeNewswire
06:00AM	Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program GlobeNewswire
Aug-05-21 05:00PM	Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs GlobeNewswire
Jul-21-21 08:00AM	Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML GlobeNewswire -5.52%
Jun-18-21 08:34AM	Implied Volatility Surging for Aprea (APRE) Stock Options Zacks
Jun-17-21 09:19AM	Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal Zacks -6.32%
Jun-16-21 09:24AM	Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients Benzinga +10.93%
08:00AM	Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint GlobeNewswire
Jun-13-21 12:45PM	Is Aprea Therapeutics, Inc. (APRE) A Good Stock To Buy? Insider Monkey
Jun-04-21 01:47AM	Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Invest In Growth? Simply Wall St.
May-21-21 06:00AM	Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit GlobeNewswire
May-18-21 06:00AM	Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-06-21 04:15PM	Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations GlobeNewswire
Apr-16-21 09:15AM	Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021 GlobeNewswire +7.64%
Apr-08-21 11:15AM	Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML) GlobeNewswire +13.64%
Mar-16-21 04:15PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations GlobeNewswire
Feb-16-21 08:04AM	Is Aprea Therapeutics, Inc. (NASDAQ:APRE) Popular Amongst Institutions? Simply Wall St.
Jan-22-21 12:00PM	What Makes Aprea Therapeutics, Inc. (APRE) a New Buy Stock Zacks
Jan-08-21 08:00AM	Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 GlobeNewswire
Dec-30-20 11:40AM	Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More Zacks
Dec-29-20 07:24PM	Dont Go Bargain Hunting on Aprea Stock, Says Analyst TipRanks -8.18%
10:32AM	Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal Zacks
Dec-28-20 04:57PM	10 Biggest Stock Gainers and Losers Today Insider Monkey -78.08%
02:22PM	Aprea Shares Slump After Cancer-Drug Trial Misses Key Goal TheStreet.com
08:00AM	Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS) GlobeNewswire
Dec-10-20 10:33PM	Is APRE A Good Stock To Buy Now? Insider Monkey
Nov-30-20 08:00AM	Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML) GlobeNewswire
Nov-23-20 10:00AM	3 Stocks with Jaw-Dropping Growth Potential Motley Fool
Nov-19-20 08:00AM	Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference GlobeNewswire
Nov-05-20 04:15PM	Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations GlobeNewswire -8.52%
Oct-30-20 04:00AM	Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today GlobeNewswire
Oct-14-20 08:00AM	Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com GlobeNewswire
Oct-07-20 08:00AM	Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548 GlobeNewswire +8.85%
Sep-29-20 08:00AM	Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors GlobeNewswire
06:28AM	Should You Take Comfort From Insider Transactions At Aprea Therapeutics, Inc. (NASDAQ:APRE)? Simply Wall St.
Sep-18-20 08:00AM	Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes GlobeNewswire
Sep-03-20 08:00AM	Aprea Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-11-20 04:15PM	Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations GlobeNewswire -7.60%
Jul-16-20 07:00AM	Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML) GlobeNewswire +5.40%
Jul-01-20 10:32AM	How Aprea Therapeutics (APRE) Stock Stands Out in a Strong Industry Zacks
07:12AM	2 Biotech Stocks That Could Soar in 2020 Motley Fool
06:30AM	We're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash Wisely Simply Wall St.
Jun-29-20 07:00AM	Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors GlobeNewswire
Jun-12-20 04:15PM	Hedge Funds Warming Up To Aprea Therapeutics, Inc. (APRE) Insider Monkey
06:00AM	Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting GlobeNewswire
Jun-11-20 10:44PM	Aprea Therapeutics (APRE) in Focus: Stock Moves 5.8% Higher Zacks
Jun-10-20 09:39AM	Is Aprea Therapeutics Stock a Buy? Motley Fool +5.75%
Jun-03-20 08:00AM	Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS) GlobeNewswire
May-27-20 09:21AM	Arcos Dorados (ARCO) in Focus: Stock Moves 10.8% Higher Zacks
May-18-20 08:00AM	Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-15-20 07:30AM	Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations GlobeNewswire +5.04%
May-11-20 10:57AM	Why Aprea Therapeutics (APRE) Stock Might be a Great Pick Zacks +6.86%
Apr-27-20 07:00AM	INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Aprea Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims GlobeNewswire
Apr-06-20 08:00AM	Aprea Therapeutics Launches New Corporate Website - www.aprea.com GlobeNewswire +6.45%
Apr-02-20 06:11AM	Have Insiders Been Buying Aprea Therapeutics, Inc. (NASDAQ:APRE) Shares This Year? Simply Wall St.
Mar-26-20 08:00AM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire -11.50%
Feb-13-20 08:00AM	Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial GlobeNewswire
Jan-30-20 07:30AM	Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation GlobeNewswire
Jan-09-20 08:00AM	Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 GlobeNewswire
Jan-03-20 05:56AM	We're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash Wisely Simply Wall St. -9.49%
Dec-17-19 10:08AM	Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS Zacks
Dec-12-19 08:30AM	Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando GlobeNewswire +10.28%
Dec-09-19 11:00AM	Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando GlobeNewswire
11:00AM	Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando GlobeNewswire
Dec-07-19 08:35AM	The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Nov-29-19 09:24AM	Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally? Zacks +6.92%
Nov-14-19 04:15PM	Aprea Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire +10.37%
Nov-11-19 04:40PM	RBC: 3 Stock Picks Set to Soar 30%+ TipRanks
Nov-06-19 09:15AM	Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting GlobeNewswire
Oct-11-19 05:01PM	Gates-Backed Vir Biotechnology Flops in Trading Debut Bloomberg
04:04PM	Insiders Roundup: Facebook, American Defense Systems GuruFocus.com
Oct-08-19 03:59PM	Large Amounts Of Insider Trading In Aprea Therapeutics Following IPO Benzinga -6.47%
Oct-07-19 04:15PM	Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +6.19%
Oct-03-19 11:09AM	Aprea Therapeutics' stock opens 3.1% above IPO price, then rises further MarketWatch
Oct-02-19 11:03PM	Aprea Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
Sep-30-19 10:21AM	IPO Outlook For The Week: Banks And Biotechs Benzinga
Sep-23-19 08:55AM	Aprea Therapeutics to offer 5 million shares in its IPO, priced at $14 to $16 each MarketWatch

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246, a small molecule p53 reactivator, which is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML); Phase I clinical trials for the treatment of relapsed/refractory TP53 mutant chronic lymphoid leukemia; and Phase I/II clinical trials in relapsed/refractory gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator, which is in Phase I clinical trials for the treatment of MDS and AML. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Seizinger Bernd R.	Director	May 18	Buy	0.71	50,000	35,500	318,580	May 19 04:31 PM
SCHADE CHRISTIAN S	Chairman & CEO	May 18	Buy	0.64	37,500	24,124	292,616	May 19 04:30 PM
Attar Eyal C.	SVP, Chief Medical Officer	Feb 28	Sale	1.73	36,000	62,280	47,000	Mar 01 05:01 PM
Korbel Gregory Alan	SVP, Chief Business Officer	Dec 01	Option Exercise	0.92	27,500	25,300	44,667	Dec 03 05:01 PM
Korbel Gregory Alan	SVP, Chief Business Officer	Dec 01	Sale	3.96	27,500	108,900	17,167	Dec 03 05:01 PM
Korbel Gregory Alan	SVP, Chief Business Officer	Nov 01	Option Exercise	0.92	27,500	25,300	44,667	Nov 03 05:34 PM
Korbel Gregory Alan	SVP, Chief Business Officer	Nov 01	Sale	5.00	27,500	137,500	17,167	Nov 03 05:34 PM
Abrahmsen Lars B.	SVP, Chief Scientific Officer	Oct 01	Option Exercise	0.92	50,000	46,000	69,000	Oct 05 05:01 PM
Korbel Gregory Alan	SVP, Chief Business Officer	Oct 01	Option Exercise	0.92	27,500	25,300	44,667	Oct 05 05:01 PM
Korbel Gregory Alan	SVP, Chief Business Officer	Oct 01	Sale	4.89	27,500	134,475	17,167	Oct 05 05:01 PM
Abrahmsen Lars B.	SVP, Chief Scientific Officer	Oct 01	Sale	4.89	50,000	244,500	19,000	Oct 05 05:01 PM
Abrahmsen Lars B.	SVP, Chief Scientific Officer	Sep 20	Option Exercise	0.92	25,000	23,000	44,000	Sep 22 05:00 PM
Korbel Gregory Alan	SVP, Chief Business Officer	Sep 20	Option Exercise	0.92	27,500	25,300	44,667	Sep 22 05:01 PM
Abrahmsen Lars B.	SVP, Chief Scientific Officer	Sep 20	Sale	4.97	25,000	124,250	19,000	Sep 22 05:00 PM
Korbel Gregory Alan	SVP, Chief Business Officer	Sep 20	Sale	4.97	32,960	163,866	17,167	Sep 22 05:01 PM
Attar Eyal C.	SVP, Chief Medical Officer	Sep 16	Sale	4.68	15,968	74,730	83,000	Sep 20 05:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience